Min as pretreatment. Sections were also examined microscopically for the look, severity and topographical distribution of immunostaining of A inside brain parenchyma (as amyloid plaques) and cerebral vessels (as CAA). A five-pointDavidson et al. Acta Neuropathologica Communications (2018) 6:Page 3 ofTable 1 Chosen demographic, genetic and neuropathological specifics for 56 men and women with Down syndromeCase ID# 1 2 3 four 5 6 7 8 9 ten 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 UKBBN ID# na na na na na na na BBN_2966 na na na na BBN_2963 na na BBN_17186 BBN_17189 BBN_17178 BBN_2981 na na BBN_2968 BBN_3356 BBN_16954 BBN_3365 na BBN_3438 BBN_16273 BBN_2978 na BBN_3020 BBN_3355 BBN_3358 BBN_3437 BBN_3353 BBN_3363 BBN_2990 BBN_3364 na na BBN_16835 BBN_3352 BBN_3439 BBN_2964 gender M F M M F M F M M F M M F F M F M F M F M M F M M M F F M M F M F F M M M M F M M F F F age 0.01 0.1 1.6 1.6 3 11 13 13 23 27 35 36 37 39 42 47 47 49 50 50 51 53 53 54 55 55 56 56 57 57 58 58 58 58 59 59 60 60 60 60 60 61 61 62 karyotype na na na na na na na 47XY21 na na na na 47XX21 na na na na na 47XY21 na na 47XY21 na na na na na na 47XY21 na 47XX21 na na na na na 47XY21 na na na na na na 47XX21 APOE na na na na na na na three,three na na na na three,4 na na na na three,four three,4 na na 3,3 three,four 2,4 3,four na 3,3 three,4 3,three na 3,three three,four three,3 2,3 2,3 3,three three,three three,3 na na 3,3 two,three three,four 3,three Thal 0 0 0 0 0 0 0 1 0 1 two 5 5 two 5 5 five 4 3 0 five 5 five 5 5 five 5 five five five five 5 five 5 5 five 5 five five 5 five 5 five five Braak 0 0 0 0 0 0 0 0 0 0 0 II I b* V VI III III II b* VI III VI VI VI V VI VI V VI V VI VI V VI VI VI VI 0 VI III VI VI V Allen CAA 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 3 1 1 1 0 1 1 2 three 2 1 1 1 3 1 1 3 2 1 three two two two 0 2 2 three two 3 Thal CAA 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 two 1 1 1 0 1 1 1 two 1 1 1 1 two 1 1 two 1 1 2 1 1 1 0 1 1 two 1Davidson et al. Acta Neuropathologica Communications (2018) 6:Web page 4 ofTable 1 Selected demographic, genetic and neuropathological facts for 56 men and women with Down syndrome (Continued)Case ID# 45 46 47 48 49 50 51 52 53 54 55 56 UKBBN ID# BBN_2965 BBN_2967 BBN_3354 BBN_3441 na BBN_2969 BBN_3440 BBN_2975 BBN_17004 na na BBN_2985 gender M F M M M M F M M M F M age 62 62 62 62 63 64 64 65 65 66 69 76 karyotype 47XY21 47XX21 na na na 47XY21 na 47XY21 na na na 47XY21 APOE 3,three three,3 3,three 2,three na three,3 3,3 three,3 three,3 na na two,3 Thal five five five 5 five 5 5 5 5 5 5 five Braak V IV VI VI VI IV VI V V V VI III Allen CAA 1 3 3 3 1 1 2 1 1 1 1 three Thal CAA 1 two 2 2 1 1 1 1 1 1 1Thal = Thal phase of amyloid Recombinant?Proteins MCP-1/CCL2 Protein deposition and Braak = Braak tau stage. CAA phenotype was assessed in accordance with Allen et al. (2014) and Thal et al. (2010). UKBBN = UK Brain Bank Network ID number, na = not available/applicablescoring system [31, 37] was employed to separately grade the severity of plaques and CAA.PlaquesGrade 0 – no amyloid plaques in present. Grade 1 – A number of amyloid plaques in each and every low power (10 microscope TIGIT Protein Cynomolgus objective) field. Grade 2 – A moderate number of amyloid plaques in every single low power field. Grade three – Lots of dispersed amyloid plaques in each low power field. Grade four – Pretty numerous, densely packed amyloid plaques in each low power field.CAAGrade 0 – No CAA in blood vessel walls in leptomeninges or brain parenchyma. Grade 1 – Occasional blood vessels with CAA in leptomeninges and/or brain parenchyma, ordinarily not occupying the full thickness of your wall. Grade two – A moderate number of blood vessels with CAA in leptomeninges and/or brain parenchyma, some occupying the full thickness of your wall. Gr.